<DOC>
	<DOCNO>NCT02736474</DOCNO>
	<brief_summary>The purpose research observe efficacy Naltrexone Bupropion combination weight loss smoking cessation baseline week 24 compare placebo .</brief_summary>
	<brief_title>Naltrexone Bupropion Combination Obese , Smoking Patients With Schizophrenia</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study . Subjects evaluation confirmation inclusion exclusion criterion meet , treat naltrexone sustain release 15mg per day bupropion sustain release 150mg per day first two week , naltrexone 25mg per day bupropion 300mg per day rest study.The purpose research observe efficacy Naltrexone Bupropion weight loss smoking cessation compare placebo .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Bupropion hydrochloride , naltrexone hydrochoride drug combination</mesh_term>
	<criteria>Diagnosis schizophrenia ; On stable atypical antipsychotic medication regimen least one month ; BMI &gt; 28 kg/m2 use BMI criterion obesity Chinese population ; Smoking least 10 cigarette daily minimum 1 year ; Desire lose weight quit smoking . Binge eat eat disorder ; Current use weight loss antidiabetic medication ; Current substance use ( except nicotine caffeine ) ; Elevated hepatic transaminase level ( &gt; 2.5x normal range ) ; Clinically significant Thyroid Stimulating Hormone（TSH） and/or thyroxine4（T4） abnormality ; History seizure disorder ; History unstable cardiac problem unstable medication condition ; Being pregnant nursing ( woman ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>